The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer.
Jing ZhaoYang WuYuan YueMin-Jiang ChenYan XuXiangning LiuXiaoyan LiuXiaoxing GaoHanping WangXiao-Yan SiWei ZhongXiao-Tong ZhangLi ZhangMengzhao WangPublished in: Thoracic cancer (2023)
Collectively, our study developed and validated two TAAb panels as valuable prognostic biomarkers for immunotherapy.